Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Phase 1 Trial to Evaluate Safety and CMV-Specific Immune Response to a pDNA CMV Trivalent Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge in Healthy, CMV- Seronegative Adults

NCT00373412 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT00373412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00373412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Phase 1 Trial to Evaluate Safety and CMV-Specific Immune Response to a pDNA CMV Trivalent Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge in Healthy, CMV- Seronegative Adults
Lead sponsor
University of California, San Francisco
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2006
Completion date
Not reported
Enrollment
16
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus infection